Genmab — Juli 2019
-
Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone. -in the JNJ PD-1 / Dara trial https://www.clinicaltrials.gov/ct2/history/NCT03357952?A=12&B=13&C=merged#StudyPageTop
-
this Tisotumab Vedotin trial seems cut off? we need to figure out why https://www.clinicaltrials.gov/ct2/history/NCT03245736?A=3&B=4&C=merged#StudyPageTop
-
A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide (DCDP) - fully recruited 120patients , all in Canada https://www.clinicaltrials.gov/ct2/history/NCT03215524?A=7&B=8&C=merged#StudyPageTop
-
Concerning the TV trial, is the answer not just to send an email to Genmab and ask?
-
@Plimsoller not sure it has to be a concern, could be a change in design of the trials or the direction, but i think a good question for Q&A?
-
De vil bruge 100 mio$ på TV
https://www.nasdaq.com/markets/ipos/company/genmab-as-777502-89779 -
Luk i dagens højeste.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind